Adaptive Biotechnologies Files 8-K on Financials
Ticker: ADPT · Form: 8-K · Filed: Feb 11, 2025 · CIK: 1478320
| Field | Detail |
|---|---|
| Company | Adaptive Biotechnologies Corp (ADPT) |
| Form Type | 8-K |
| Filed Date | Feb 11, 2025 |
| Risk Level | low |
| Pages | 2 |
| Reading Time | 2 min |
| Key Dollar Amounts | $0.0001 |
| Sentiment | neutral |
Sentiment: neutral
Topics: financial-reporting, 8-k
Related Tickers: ADPT
TL;DR
ADPT filed an 8-K on Feb 11, 2025, detailing financial results and operations.
AI Summary
Adaptive Biotechnologies Corporation filed an 8-K on February 11, 2025, reporting on its results of operations and financial condition. The filing includes financial statements and exhibits, with the company's principal executive offices located at 1165 Eastlake Avenue East, Seattle, Washington.
Why It Matters
This 8-K filing provides investors with crucial updates on Adaptive Biotechnologies' financial performance and operational status.
Risk Assessment
Risk Level: low — This filing is a routine disclosure of financial information and does not indicate any immediate or significant risks.
Key Players & Entities
- Adaptive Biotechnologies Corporation (company) — Registrant
- February 11, 2025 (date) — Date of Report
- 1165 Eastlake Avenue East, Seattle, Washington 98109 (address) — Principal Executive Offices
- 001-38957 (company_id) — Commission File Number
- 27-0907024 (company_id) — IRS Employer Identification No.
FAQ
What specific financial information is being reported in this 8-K?
The 8-K filing indicates it covers 'Results of Operations and Financial Condition' and includes 'Financial Statements and Exhibits'.
When was this 8-K report filed?
The report was filed on February 11, 2025.
What is the primary business of Adaptive Biotechnologies Corporation?
Adaptive Biotechnologies Corporation is in the 'BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES)' industry, SIC code 2836.
Where are Adaptive Biotechnologies Corporation's principal executive offices located?
The principal executive offices are located at 1165 Eastlake Avenue East, Seattle, Washington 98109.
What is the Commission File Number for Adaptive Biotechnologies Corporation?
The Commission File Number is 001-38957.
Filing Stats: 508 words · 2 min read · ~2 pages · Grade level 12.6 · Accepted 2025-02-11 16:15:09
Key Financial Figures
- $0.0001 — ch registered Common stock, par value $0.0001 per share ADPT The NASDAQ Stock Mar
Filing Documents
- adpt-20250211.htm (8-K) — 52KB
- adpt-ex99_1.htm (EX-99.1) — 664KB
- img119828894_0.jpg (GRAPHIC) — 8KB
- 0000950170-25-017915.txt ( ) — 872KB
- adpt-20250211.xsd (EX-101.SCH) — 30KB
- adpt-20250211_htm.xml (XML) — 5KB
02
Item 2.02 Results of Operations and Financial Condition. On February 11, 2025, Adaptive Biotechnologies Corporation (the " Company ") issued a press release regarding the Company's financial results for the quarter and fiscal year ended December 31, 2024. A copy of the press release is attached as Exhibit 99.1 and incorporated herein by reference. The information in this Item 2.02 and the press release attached as Exhibit 99.1 hereto shall not be deemed to be "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the " Exchange Act "), nor shall such information be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as shall be expressly set forth by specific reference in such filing.
Financial Statements and Exhibits
Financial Statements and Exhibits. (d) Exhibits. Exhibit Number Description 99.1 Press Release dated February 11, 2025 104 Cover Page Interactive Data File (embedded within the Inline XBRL document)
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized. Adaptive Biotechnologies Corporation Date: February 11, 2025 By: /s/ Kyle Piskel Kyle Piskel Chief Financial Officer